Dx & Vx Co

Dx & Vx Co EBIT per Share

The EBIT per Share of Dx & Vx Co (180400.KQ) as of Nov 5, 2026 is -297.70 KRW. In the previous year, EBIT per Share was 91.81 KRW — a change of -424.25% (lower).

EBIT per Share

-297.70KRW

YoY

-424.25%

Last updated:

EBIT per Share of Dx & Vx Co is 2025 -297.70 KRW. EBIT per Share of Dx & Vx Co was 2024 91.81 KRW. It decreases by -424.25% lower compared to the previous year.

The Dx & Vx Co EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2016
-76.59 KRW
Jan 1, 2017
-365.67 KRW
Jan 1, 2018
-571.43 KRW
Jan 1, 2019
-320.35 KRW
Jan 1, 2020
-262.24 KRW
Jan 1, 2021
-131.97 KRW
Jan 1, 2022
91.81 KRW
Jan 1, 2025
-297.70 KRW
The Dx & Vx Co EBIT per Share history
YEAREBIT per ShareYoY
-297.70KRW-424.25%
91.81KRW-169.57%
-131.97KRW-49.68%
-262.24KRW-18.14%
-320.35KRW-43.94%
-571.43KRW+56.27%
-365.67KRW+377.43%
-76.59KRW-221.43%
63.08KRW+50.51%
41.91KRW-2,012.80%
-2.19KRW-106.19%
35.38KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dx & Vx Co Stock analysis

What does Dx & Vx Co do? Dx & Vx Co., Ltd. generates revenue through the Molecular Diagnosis Business segment, which focuses on manufacturing and selling DNA chips, PCR chips, and related diagnostic reagents for molecular diagnosis. The company also produces enzymes and experimental reagents for biological research, targeting laboratories and healthcare facilities that require molecular diagnostic tools. Its products are sold to institutions involved in medical testing and research, leveraging the demand for advanced diagnostic solutions in healthcare. The company's revenue streams are derived from direct sales of these specialized products to the healthcare and research sectors. Dx & Vx Co., Ltd. operates within the molecular diagnostics market, offering DNA chips, PCR chips, and diagnostic reagents as core products. The company's focus on manufacturing and selling these items positions it as a provider of essential tools for molecular biology applications. Sales are directed toward laboratories and healthcare providers seeking to enhance their diagnostic capabilities through cutting-edge technology. The business model relies on consistent demand for molecular diagnostic equipment and reagents within the medical and research industries. Dx & Vx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dx & Vx Co stock

EBIT per Share of Dx & Vx Co is -297.70 KRW in 2025.

EBIT per Share of Dx & Vx Co changed from 91.81 KRW to -297.70 KRW, representing a -424.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Dx & Vx Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Dx & Vx Co

All Key Metrics — Dx & Vx Co